Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 72,569	$ 59,624
Marketable securities	90,562	153,978
Accounts receivable	1,216	342
Prepaid expenses and other current assets	2,934	3,958
Total current assets	167,281	217,902
Marketable securities	8,000
Property and equipment, net	20,468	24,688
Operating lease right-of-use assets	20,162	21,110
Goodwill	8,537	8,167
Intangible assets, net	19,405	18,978
Restricted cash	1,750	468
Other assets	1,283
Total assets	246,886	291,313
Current liabilities:
Accounts payable	325	414
Accrued clinical trial and manufacturing expenses	2,051	4,253
Accrued expenses and other liabilities	6,972	8,181
Operating lease liabilities	1,715	1,803
Deferred revenue	3,786	6,950
Total current liabilities	14,849	21,601
Contingent consideration	2,205	1,051
Deferred revenue	159,754	166,963
Deferred tax liabilities	3,687	3,527
Operating lease liabilities	30,414	31,636
Other long-term liabilities	1,443	940
Total liabilities	212,352	225,718
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2020 and December 31, 2019
Common stock, $0.0001 par value; 300,000,000 shares authorized; 16,268,861 and 16,147,137 shares issued and outstanding at September 30, 2020 and December 31, 2019	2	2
Additional paid-in capital	558,920	552,083
Accumulated other comprehensive income	1,246	414
Accumulated deficit	(525,634)	(486,904)
Total stockholders’ equity	34,534	65,595
Total liabilities and stockholders’ equity	$ 246,886	$ 291,313